Moxifloxacin for tuberculosis - Authors' reply

The Lancet Infectious Diseases

Volumn 12, Issue 3, 2012, Pages 177-178

  Cox, Helen ^a,b   Ford, Nathan ^a,b   Von Schoen Angerer, Tido ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; NEW DRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; EPIDEMIC; HEALTH CARE NEED; HUMAN; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESEARCH PRIORITY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

EID: 84857147804     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70015-4     Document Type: Letter

References (5)

1. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
2. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response; 2010 World Health Organization, (accessed March 23, 2010). http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.
3. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006, 12:7-11.
4. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C Totally drug-resistant tuberculosis in India. Clin Infect Dis 2011, published online Dec 21. 10.1093/cid/cir889.
5. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359:563-574.